ニュースルーム
MiRXESの最新情報をお届けします
注目


Mirxes Holding Company Limited (the “Company”; Stock code: 2629) marked a significant milestone today as its shares debuted on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX), closing its first day of trade as a new biotech unicorn with a market capitalisation of HK$8.29 billion (US$1.06 billon).
Learn More

Mirxes, a leading RNA technology company specializing in early cancer detection and precision medicine, today announced a US$40 million structured financing transaction with CBC Group’s R-Bridge Healthcare Fund (“R-Bridge”). This partnership will provide critical support for Mirxes’ ambitious growth and expansion into key global markets.
Learn More

In a First-In-Singapore collaboration, leading RNA technology company Mirxes and PULSE TCM, a renowned provider of traditional Chinese Medicine (TCM) services, today launched the holistic “East Meets West” Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare for a Healthier Singapore.
Learn More

The National University Hospital (NUH) and Mirxes are proud to announce the official opening of the NUH DMOC@Biopolis, one of Singapore’s first publicprivate partnership centres for specialty molecular testing. The NUH DMOC@Biopolis is an extension of NUH’s Diagnostic Molecular Oncology Centre (DMOC) that co-locates and integrates with Mirxes’ clinical laboratory, M Diagnostics at Biopolis. The Centre was inaugurated today by Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation (NRF), Mr Heng Swee Keat.
Learn More

Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S.
Learn Moreメディアリリース
科学技術の革新と開発にたゆまず取り組み、シンガポールから世界へ、新しい製品を市場に送り出し続けている当社の最新ニュースや活動をご紹介します。
15 February 2022
22 November 2021
15 November 2021
23 October 2021
1 October 2021
MiRXES announced today the appointment of Mr. Cher Hwa TEO as Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff. As the SVP of Health Innovation Delivery, Mr. Teo will help embed MiRXES into the Singapore healthcare ecosystem through downstream market access efforts by driving greater advocacy towards the adoption of MiRXES’s technology and products.
21 September 2021
20 September 2021

28 July 2021
Dr. Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnostics.

8 July 2021

24 February 2021
メディア掲載情報
当社に関する最新のメディア掲載情報をご紹介します。
2 Feb 2022
6 Dec 2021
コラボレーション
パートナーの紹介
15 Sep 2021
31 Aug 2021
インサイト
バイオテクノロジー業界の最前線を知るためのナレッジベースへようこそ。


メディア・投資に関するお問い合わせ
